-
公开(公告)号:US20070093451A1
公开(公告)日:2007-04-26
申请号:US11607919
申请日:2006-12-04
申请人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
发明人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
IPC分类号: A61K31/724
CPC分类号: A61K31/565 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/567 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/6951 , B82Y5/00 , C08B37/0015 , A61K2300/00
摘要: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
摘要翻译: 提供包含雌激素和环糊精之间的低剂量灵敏复合物的药物组合物具有改进的稳定性。 在具体实施方案中,组合物包含颗粒制剂中乙炔雌二醇和β-环糊精之间的复合物,在另一个实施方案中,该组合物包含有限量的聚乙烯吡咯烷酮,因为发现该赋形剂降解乙炔雌二醇。 此外,提供了用于提高组合物中雌激素的稳定性和制造这种稳定组合物的方法。 基本上,在仔细控制相对湿度的情况下制造颗粒制剂。
-
公开(公告)号:US06958326B2
公开(公告)日:2005-10-25
申请号:US10022845
申请日:2001-12-20
申请人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
发明人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
IPC分类号: A61K47/32 , A61K31/565 , A61K31/566 , A61K31/57 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/40 , A61K47/48 , A61P15/00 , A61P15/18 , C08B37/00 , A01N43/04
CPC分类号: A61K31/565 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/567 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/6951 , B82Y5/00 , C08B37/0015 , A61K2300/00
摘要: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
摘要翻译: 提供包含雌激素和环糊精之间的低剂量灵敏复合物的药物组合物具有改进的稳定性。 在具体实施方案中,组合物包含颗粒制剂中乙炔雌二醇和β-环糊精之间的复合物,在另一个实施方案中,该组合物包含有限量的聚乙烯吡咯烷酮,因为发现该赋形剂降解乙炔雌二醇。 此外,提供了用于提高组合物中雌激素的稳定性和制造这种稳定组合物的方法。 基本上,在仔细控制相对湿度的情况下制造颗粒制剂。
-
公开(公告)号:US20050182024A1
公开(公告)日:2005-08-18
申请号:US11102681
申请日:2005-04-11
申请人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
发明人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
IPC分类号: A61K47/32 , A61K31/565 , A61K31/566 , A61K31/57 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/40 , A61K47/48 , A61P15/00 , A61P15/18 , C08B37/00 , A61K31/56
CPC分类号: A61K31/565 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/567 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/6951 , B82Y5/00 , C08B37/0015 , A61K2300/00
摘要: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
摘要翻译: 提供包含雌激素和环糊精之间的低剂量灵敏复合物的药物组合物具有改进的稳定性。 在具体实施方案中,组合物包含颗粒制剂中乙炔雌二醇和β-环糊精之间的复合物,在另一个实施方案中,该组合物包含有限量的聚乙烯吡咯烷酮,因为发现该赋形剂降解乙炔雌二醇。 此外,提供了用于提高组合物中雌激素的稳定性和制造这种稳定组合物的方法。 基本上,在仔细控制相对湿度的情况下制造颗粒制剂。
-
公开(公告)号:US07569557B2
公开(公告)日:2009-08-04
申请号:US11607919
申请日:2006-12-04
申请人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
发明人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
IPC分类号: A01N43/04 , A61K31/715
CPC分类号: A61K31/565 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/567 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/6951 , B82Y5/00 , C08B37/0015 , A61K2300/00
摘要: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
摘要翻译: 提供包含雌激素和环糊精之间的低剂量灵敏复合物的药物组合物具有改进的稳定性。 在具体实施方案中,组合物包含颗粒制剂中乙炔雌二醇和β-环糊精之间的复合物,在另一个实施方案中,该组合物包含有限量的聚乙烯吡咯烷酮,因为发现该赋形剂降解乙炔雌二醇。 此外,提供了用于提高组合物中雌激素的稳定性和制造这种稳定组合物的方法。 基本上,在仔细控制相对湿度的情况下制造颗粒制剂。
-
公开(公告)号:US07163931B2
公开(公告)日:2007-01-16
申请号:US11102681
申请日:2005-04-11
申请人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
发明人: Thomas Backensfeld , Wolfgang Heil , Ralph Lipp
IPC分类号: A01N43/04 , A61K31/715 , C08B37/16
CPC分类号: A61K31/565 , A61K9/1652 , A61K9/1694 , A61K9/2018 , A61K9/2027 , A61K9/205 , A61K9/2054 , A61K31/567 , A61K31/585 , A61K31/715 , A61K31/724 , A61K47/6951 , B82Y5/00 , C08B37/0015 , A61K2300/00
摘要: Pharmaceutical compositions comprising low doses of sensitive complexes between an estrogen and a cyclodextrin are provided with improved stability. In specific embodiments the composition comprises a complex between ethinyl estradiol and β-cyclodextrin in a granulate preparation and in yet another embodiment the composition comprises a limited amount of polyvinylpyrrolidone since this excipient was found to degrade ethinyl estradiol. Furthermore, a method for improving the stability of an estrogen in a composition and for manufacturing such a stable composition is provided. Essentially, the granulate preparation are manufactured under careful control of the relative humidity.
-
公开(公告)号:US06610670B2
公开(公告)日:2003-08-26
申请号:US10022846
申请日:2001-12-20
申请人: Thomas Backensfeld , Wolfgang Heil
发明人: Thomas Backensfeld , Wolfgang Heil
IPC分类号: A01N4304
CPC分类号: B82Y5/00 , A61K31/585 , A61K47/6951 , C08B37/0015 , Y10S514/843
摘要: Described are inclusion complexes formed between cyclodextrin and drospirenone. In a specific embodiment of the invention, the cyclodextrin is &bgr;-cyclodextrin. The invention further relates to methods of providing such an inclusion complex, and to the use of said inclusion complex for improving the solubility of drospirenone, for providing pharmaceutical compositions, for use as a medicament in the treatment of symptoms associated with menopause and in female contraception.
-
公开(公告)号:US20060058272A1
公开(公告)日:2006-03-16
申请号:US11266395
申请日:2005-11-04
申请人: Juergen Hilman , Wolfgang Heil , Ralph Lipp , Renate Heithecker
发明人: Juergen Hilman , Wolfgang Heil , Ralph Lipp , Renate Heithecker
IPC分类号: A61K31/56
CPC分类号: A61K31/585 , A61K31/56 , A61K31/567 , A61K2300/00
摘要: A pharmaceutical composition comprises, as a first active agent, 6β,7β;15β,16β-dimethylene-3-oxo-17α-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17α-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
-
公开(公告)号:US06787531B1
公开(公告)日:2004-09-07
申请号:US09654227
申请日:2000-08-31
申请人: Juergen Hilman , Wolfgang Heil , Ralph Lipp , Renate Heithecker , Michael Huempel , Johannes W. Tack
发明人: Juergen Hilman , Wolfgang Heil , Ralph Lipp , Renate Heithecker , Michael Huempel , Johannes W. Tack
IPC分类号: A61K3156
CPC分类号: A61K31/585 , A61K31/56 , A61K31/567 , A61K2300/00
摘要: A pharmaceutical composition comprises, as a first active agent, 6&bgr;,7&bgr;;15&bgr;,16&bgr;-dimethylene-3-oxo-17&agr;-pregn-4-ene-21,17-carbolactone (drospirenone) in an amount corresponding to a daily dosage, on administration of the composition, of from about 2 mg to about 4 mg, and, as a second active agent, 17&agr;-ethinylestradiol (ethinylestradiol) in an amount corresponding to a daily dosage of from about 0.01 mg to about 0.05 mg, together with one or more pharmaceutically acceptable carriers or excipients. In a specific embodiment, the composition consists of a number of separately packaged and individually removable daily dosage units placed in a packaging unit and intended for oral administration for a period of at least 21 consecutive days, wherein said daily dosage units comprises the combination of drospirenone and ethinylestradiol. The composition may further comprise 7 or less daily dosage units containing no active agent or containing ethinylestradiol alone.
摘要翻译: 作为第一活性剂的药物组合物包含对应于每日剂量的量的6β,7beta,15beta,16beta-二亚甲基-3-氧代-17α-孕-4-烯-21,17-碳内酯(屈螺酮) 在约2mg至约4mg的施用组合物上,并且作为第二活性剂,以对应于约0.01mg至约0.05mg的日剂量的量的17α-炔炔雌二醇(炔雌醇)与 一个或多个药学上可接受的载体或赋形剂。在一个具体实施方案中,组合物由多个单独包装的和单独可移除的每日剂量单位组成,放置在包装单元中并且用于口服给药至少连续21天,其中 所述日剂量单位包括屈螺酮和炔雌醇的组合。 该组合物可以进一步包含7个或更少的不含活性剂或仅含有炔雌醇的日剂量单位。
-
公开(公告)号:US07148207B2
公开(公告)日:2006-12-12
申请号:US10324141
申请日:2002-12-20
申请人: Wolfgang Heil , Ulf Tistam , Ralph Lipp , Johannes-Wilhelm Tack
发明人: Wolfgang Heil , Ulf Tistam , Ralph Lipp , Johannes-Wilhelm Tack
IPC分类号: A61K31/7076 , C07H19/00
CPC分类号: A61K9/2054 , A61K9/2018 , A61K9/2866
摘要: This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants.
-
公开(公告)号:US20080141667A1
公开(公告)日:2008-06-19
申请号:US11612150
申请日:2006-12-18
IPC分类号: F01N7/00
CPC分类号: H01M8/0662 , F01N1/082 , F01N1/083 , F01N1/24
摘要: One embodiment of the invention includes a product including a fuel-cell exhaust diffuser; an air funnel; and at least two exhaust tubes attached to the diffuser.
摘要翻译: 本发明的一个实施例包括一种包括燃料电池排气扩散器的产品; 一个空气漏斗 和至少两个连接到扩散器的排气管。
-
-
-
-
-
-
-
-
-